top of page
Search

Jiajie Biomedical's April revenue increased by 3% year-on-year; strong sales of its new product, "Pure Fish Oil," will boost future performance.

Jiajie Biotech's revenue in April was NT$37.23 million, a 3% year-on-year increase. The new product, "90% Pure Fish Oil," has received a strong market response. It uses supercritical extraction technology and high-purity Omega-3, and is expected to become a driver of future revenue growth.


Lifestyle Center / Comprehensive Report

Jiajie Biomedical's new product, "90% Pure Fish Oil," has performed exceptionally well, receiving high praise from the market. (Image/Jiajie Biomedical official website)


Jiajie Biomedical Co., Ltd. (stock code: 4109), a leading nutrition and health brand under the Taiwan Steel Group, announced on the 10th that its revenue in April 2025 was NT$37.23 million, a 3% increase compared to the same period last year; the cumulative revenue for the first four months reached NT$169.96 million, but a 13% decrease year-on-year.


Image provided by Jakarta Biomedical


Jiajie Biotech pointed out that, after in-depth observation of market trends and diverse consumer needs, the company recently launched three new products, including: "Strengthening and Stable Algae Calcium x Natto Extract", "Male and Upright Maca x Cordyceps militaris", and "90% Pure Fish Oil for Circulating Metabolism". Among them, "90% Pure Fish Oil for Circulating Metabolism" has performed the best and has been well received by the market.

This product emphasizes the brand concept of "natural and locally sourced," employing advanced supercritical extraction technology to balance freshness, safety, and sustainability goals. It has also passed third-party certified testing, boasting a total Omega-3 fatty acid content of up to 99%. Furthermore, considering consumer convenience, the product is designed as a small capsule only 1.4 cm in length, increasing its acceptability for daily supplementation.


According to the sales results in April, the effects of the new products have gradually become apparent. As the market continues to develop, it is expected to help improve overall revenue performance and inject growth momentum into the company.






 
 
  • Facebook
  • YouTube

3F, No. 61, Jiuru 1st Road, Sanmin District, Kaohsiung City, Taiwan

3F., No.61, Jiuru 1st Rd., Sanmin Dist., Kaohsiung City 807, Taiwan

COPYRIGHT © 2025 - JiaJie Biomedical | ALL RIGHTS RESERVED

bottom of page